These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 23196275)

  • 61. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening.
    Zhou J; Zhao J; Sun K; Wang B; Wang L; Chen X; Zheng J; You Q; Wang X; Ding W; Zhou J
    PLoS One; 2014; 9(3):e92828. PubMed ID: 24667320
    [TBL] [Abstract][Full Text] [Related]  

  • 62. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
    Singh A; Kumar R; Shetty O; Desai S; Rane S
    Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer.
    Cruz-Rico G; Avilés-Salas A; Segura-González M; Espinosa-García AM; Ramírez-Tirado LA; Morales-Oyarvide V; Rojas-Marín C; Cardona AF; Arrieta O
    Am J Clin Oncol; 2017 Dec; 40(6):631-638. PubMed ID: 26270443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
    Selinger CI; Rogers TM; Russell PA; O'Toole S; Yip P; Wright GM; Wainer Z; Horvath LG; Boyer M; McCaughan B; Kohonen-Corish MR; Fox S; Cooper WA; Solomon B
    Mod Pathol; 2013 Dec; 26(12):1545-53. PubMed ID: 23743928
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Assessment of ALK rearrangement in non-small cell lung cancer: using enhancing immunohistochemical way and fluorescence in situ hybridization].
    Meng H; Gao X; Zhang L; Liu F; Li W
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):75-9. PubMed ID: 25676399
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
    Trejo Bittar HE; Luvison A; Miller C; Dacic S
    Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
    Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
    Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 69. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
    Pyo JS; Kang G; Sohn JH
    Int J Biol Markers; 2016 Dec; 31(4):e413-e421. PubMed ID: 27338643
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
    Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL
    J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
    Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
    Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
    Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin.
    Moatter S; Anwar N; Moatter T; Pervez S
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1735-1738. PubMed ID: 29938474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.
    Zhiwei W; Yuan J; Yihui Y; Xin H; Jingtao C; Lei S; Yongjian D
    Thorac Cancer; 2017 Sep; 8(5):471-476. PubMed ID: 28742247
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.
    van der Wekken AJ; Pelgrim R; 't Hart N; Werner N; Mastik MF; Hendriks L; van der Heijden EHFM; Looijen-Salamon M; de Langen AJ; Staal-van den Brekel J; Riemersma S; van den Borne BE; Speel EJM; Dingemans AC; Hiltermann TJN; van den Berg A; Timens W; Schuuring E; Groen HJM
    Clin Cancer Res; 2017 Aug; 23(15):4251-4258. PubMed ID: 28183714
    [No Abstract]   [Full Text] [Related]  

  • 78. Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
    Fiset PO; Labbé C; Young K; Craddock KJ; Smith AC; Tanguay J; Pintilie M; Wang R; Torlakovic E; Cheung C; da Cunha Santos G; Ko HM; Boerner SL; Hwang DM; Leighl NB; Tsao MS
    Cancer; 2019 Nov; 125(22):4043-4051. PubMed ID: 31390053
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ALK Expression in Angiomatoid Fibrous Histiocytoma: A Potential Diagnostic Pitfall.
    Cheah AL; Zou Y; Lanigan C; Billings SD; Rubin BP; Hornick JL; Goldblum JR
    Am J Surg Pathol; 2019 Jan; 43(1):93-101. PubMed ID: 29877921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.